{"id":23500,"date":"2001-12-07T12:51:17","date_gmt":"2001-12-07T18:51:17","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=23500"},"modified":"2018-04-14T02:01:03","modified_gmt":"2018-04-14T07:01:03","slug":"23500","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/23500\/","title":{"rendered":"Not\u00edcias e notas sobre sa\u00fade animal de 7 de dezembro de 2001"},"content":{"rendered":"

****************************************************************
\nBrakke Consulting’s
\nAnimal Health News & Notes for December 7, 2001<\/strong>
\nCopyright © Brakke Consulting, Inc.
\n****************************************************************
\nThe 2001 Brakke Flea & Heartworm Study is now available.
\nOne more week to receive the discounted price – ORDER YOUR COPY NOW!<\/p>\n

Each fall, Brakke Consulting updates its annual report on the US Flea Control and Heartworm Markets.  In addition to updated sales figures for the major products, the study includes two new surveys of small animal veterinarians and retail pet stores, as well as a special section covering the effect of the September 11 terrorist attacks on veterinary income.  The study also includes information on Fort Dodge’s new ProHeart 6 heartworm preventative, Novartis’ Capstar flea adulticide, the arrival of generic ivermectin heartworm preventatives, and a review of products in development. <\/p>\n

Orders placed before December 15 will receive a discounted price of $3,250.  After that time, the regular price of $4,000 will be charged.  To order your copy of the report, please contact us at lfondon@brakkeconsulting.com<\/a>  or call (972) 243-4033. <\/p>\n

****************************************************************
\nCompany News Releases<\/p>\n

>  Bayer AG’s supervisory board is expected to approve a plan transforming the group’s four divisions into separate legal entities. Bayer has been urged by investors for years to separate its traditionally higher-margin drugs unit from its chemicals business.  The company has previously announced plans to put its key healthcare and agro-chemicals divisions into separate legal units, and has said it might do this with its chemicals unit. Its fourth division is polymers. (Reuters)<\/p>\n

>  The FDA approved a supplemental new animal drug application (NADA) filed by Pfizer, Inc. that provides for a once daily, 2-milligram per pound (mg\/lb) dosage of carprofen (Rimadyl), by oral caplet, for the relief of pain and inflammation associated with osteoarthritis in dogs. Rimadyl was previously labeled for twice-daily dosing.  (AnimalNet – Federal Register)<\/p>\n

>  The FDA approved an abbreviated new animal drug application (ANADA) filed by First Priority, Inc. The ANADA provides for oral use of ivermectin solution in horses for the treatment and control of various species of internal and cutaneous parasites. (AnimalNet – Federal Register)<\/p>\n

>  ABAXIS, Inc. announced the introduction of the VetScan Canine Heartworm Antigen Test and the signing of an exclusive multi-year OEM\/distribution agreement with SA Scientific, a privately held developer and manufacturer of a wide-range of one-step rapid tests for various diseases. The VetScan Canine Heartworm Antigen Test is the first of a portfolio of rapid antigen tests ABAXIS intends to introduce to the veterinary market in the next 12 months. Future products are expected to address Feline Heartworm, Canine Parvovirus Antigen test and Feline Leukemia Virus Antigen test. (PRNewswire)<\/p>\n

>  ImmuCell Corporation announced that the USDA approved Tip-Test: BLV, the Company’s Bovine Leukemia Virus antibody test kit. The product licensure represents ImmuCell’s fourth USDA approved product for the dairy and beef industry. Tip-Test: BLV is the Company’s second diagnostic product utilizing its rapid on-site testing technology; the Company obtained USDA approval of Tip-Test: Johne’s in December 1999. (Business Wire)<\/p>\n

>  Smithfield Foods Inc. and meatpacker American Foods Group Inc. have ended discussions for Smithfield’s planned acquisition of American Foods. The companies did not disclose why talks were terminated.  The companies had announced an agreement in principle for the deal. If it had been completed, Smithfield’s third beef processing acquisition of the year would have propelled the company into the number four position in the industry, with a 9% market share. (AgWeb)<\/p>\n

>  CANADA   Milestone Medica, Foragen and Immunotech Developments Inc. announced a C$1.8 million deal that will focus on developing a novel treatment for stress-related conditions in animals. The investment will be directed at developing a new anti-stress compound that will enhance animal health and counteract disease and weight loss in animals. (AnimalNet)<\/p>\n

*******************************************************************
\nBrakke Consulting’s 2002 Animal Health Industry Overview<\/p>\n

Every year Brakke Consulting inaugurates our Annual Industry Overview presentations at the North American and Western Veterinary Conferences.  Seating for these presentations is always limited and fills quickly.  We will be presenting the Overview twice at the North American Conference in Orlando and once at the Western Conference in Las Vegas.  You can register online by visiting our website homepage at www.brakkeconsulting.com<\/a> and clicking on the time of the presentation at the location you wish to attend.  This information is located towards the bottom of our homepage beneath the world map.  Registration is $295.00 ($325.00 after 1\/4\/02) for the first attendee at the conference location from a company and $245.00 ($275.00 after 1\/4\/02) for each additional attendee at the conference location from the same company.<\/p>\n

– North American Veterinary Conference
\n Monday, January 14, 2002
\n 9:30 am OR 1:30 pm
\n– Western Veterinary Conference
\n Wednesday, February 13, 2002
\n 9:00 am<\/p>\n

For additional information please contact Jane Morgan at 972-243-4033 or by email at jmorgan@brakkeconsulting.com<\/a><\/p>\n

*******************************************************************
\nAnimal Health News<\/p>\n

>  Veterinary Business Development Ltd. is sponsoring a conference entitled “EU Expansion: The Impact on Animal Health, Food Safety, and Agriculture.  Can We Survive It?” December 12-13 in Brussels.  This conference will address the problems and opportunities that future enlargement of the European Community will bring to agriculture, food safety, and animal health.  For more information, contact Dr. G.N. Henderson at nickhen@pncl.co.uk<\/a>.<\/p>\n

>  US   Genesis Bioventures, Inc. (formerly BioLabs, Inc.) announced that one of its portfolio companies, Prion Developmental Laboratories, Inc. (PDL) is currently in late-stage discussions with a European pharmaceutical company to provide them with an easy-to-use, patents pending rapid strip test for detecting Bovine Spongiform Encephalopathy (BSE).  The lateral flow strip test, developed by scientists at PDL, has been tested at Case Western Reserve University and the Institute for Basic Research and Developmental Disabilities. It is similar to a home pregnancy test and will be used on-site using brain tissue. The test takes less than five minutes to complete with
\naccurate, easily interpreted results. (PRNewswire)<\/p>\n

>  JAPAN   Officials have confirmed Japan’s third case of bovine spongiform encephalopathy.  The most recent case was detected in a cow from the central Gunma Prefecture. The government is investigating whether inadequately sterilized meat and bone meal imported from Italy might be partly to blame for the outbreak. (Meating Place)<\/p>\n

>  FINLAND  Concern is mounting that Finland, one of three European countries not to have a case of BSE, may be facing its first incident.  Routine tests on a slaughtered sick cow could have revealed BSE. The Finnish national veterinary medicines institute says that the first results are suspicious but BSE cannot be confirmed for at least a week or two while other tests are being carried out. The suspect case is in a cow born in 1995 on a farm in Uleaaborg in the north of Finland. (Wattnet)<\/p>\n

*******************************************************************
\nBrakke Consulting Viewpoint<\/p>\n

We believe 2002 will provide a great deal of excitement in the consolidation area.  The level of top- and bottom-line growth being forced upon animal health management by the parent companies could make it a rather uncomfortable year.  We see total market next year to be flat with maybe best case being a 1% or 2% growth.  The result before year-end 2002 will be the consolidation of one or more of the top 15 companies.  While no company has their animal health division for sale, we are finding an increasing degree of concern over the animal health growth opportunity. There is not a lot of good news to report regarding the future of animal health other than most of these businesses are quite profitable. In addition, the pipeline of new products for introduction in the next 12 months seems to be at an all time low.  Most companies are scrambling to find a few new products either via reformulation, acquisition, or in-licensing.<\/p>\n

We believe that consolidations will provide the best opportunity for growth in manufacturers, distributors, and producers in 2002.  Brakke Consulting has a full line of services in the merger, divestiture, and licensing area.  We would be pleased to assist your firm with your needs in this area in 2002.<\/p>\n

[Ron Brakke]<\/p>\n

********************************************************************
\nThis electronic newsletter is the sole property of Brakke Consulting, Inc.
\nAny use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.<\/p>\n

For more information about Brakke Consulting’s services and syndicated studies, visit our website at www.brakkeconsulting.com<\/a>.<\/p>\n

If this email was forwarded to you and you would like to be added to the circulation list, please send an email to info@brakkeconsulting.com<\/a> (mailto:info@brakkeconsulting.com<\/a>) with “add” typed in the subject line, and your name, title, and company affiliation in the body of the message, and you will be added to the mailing list.  If you would like for us to remove your name from the circulation list, please send an email to info@brakkeconsulting.com<\/a> (mailto:info@brakkeconsulting.com<\/a>) with “remove” and your name typed in the subject line.<\/p>\n","protected":false},"excerpt":{"rendered":"

************************************************** ************** Not\u00edcias e notas sobre sa\u00fade animal da Brakke Consulting de 7 de dezembro de 2001 Copyright \u00a9 Brakke Consulting, Inc. ***************** *********************************************** O Brakke 2001 O estudo sobre pulgas e dirofilariose j\u00e1 est\u00e1 dispon\u00edvel. Mais uma semana para receber o pre\u00e7o com desconto \u2013 PE\u00c7A SUA C\u00d3PIA AGORA! A cada outono, a Brakke Consulting atualiza seu relat\u00f3rio anual sobre os mercados de controle de pulgas e dirofilariose dos EUA. Al\u00e9m dos n\u00fameros de vendas atualizados dos principais produtos, o estudo inclui duas novas pesquisas com veterin\u00e1rios de pequenos animais e lojas de varejo de animais de estima\u00e7\u00e3o, bem como uma se\u00e7\u00e3o especial que cobre o efeito dos ataques terroristas de 11 de setembro nas receitas veterin\u00e1rias. O estudo tamb\u00e9m inclui informa\u00e7\u00f5es sobre o novo preventivo contra dirofilariose ProHeart 6 da Fort Dodge, o adulticida contra pulgas Capstar da Novartis, a chegada de preventivos gen\u00e9ricos de ivermectina contra dirofilariose e uma revis\u00e3o de produtos em desenvolvimento. Os pedidos feitos antes de 15 de dezembro receber\u00e3o um pre\u00e7o com desconto de $3.250. Ap\u00f3s esse per\u00edodo, ser\u00e1 cobrado o pre\u00e7o normal de $4.000. Para solicitar sua c\u00f3pia do relat\u00f3rio, entre em contato conosco pelo e-mail lfondon@brakkeconsulting.com ou ligue para (972) 243-4033. ************************************************** ************** Comunicados \u00e0 imprensa da empresa > Espera-se que o conselho supervisor da Bayer AG aprove um plano transformando as quatro divis\u00f5es do grupo em entidades legais separadas. H\u00e1 anos que a Bayer tem sido instada por investidores a separar a sua unidade de medicamentos, tradicionalmente com margens mais elevadas, do seu neg\u00f3cio de produtos qu\u00edmicos. A empresa j\u00e1 havia anunciado planos para colocar<\/p>\n

Ver postagem completa<\/a><\/div>\n

;<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-23500","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"\nNews from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/23500\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"**************************************************************** Brakke Consulting’s Animal Health News & Notes for December 7, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** The 2001 Brakke Flea & Heartworm Study is now available. One more week to receive the discounted price – ORDER YOUR COPY NOW! Each fall, Brakke Consulting updates its annual report on the US Flea Control and Heartworm Markets.  In addition to updated sales figures for the major products, the study includes two new surveys of small animal veterinarians and retail pet stores, as well as a special section covering the effect of the September 11 terrorist attacks on veterinary income.  The study also includes information on Fort Dodge’s new ProHeart 6 heartworm preventative, Novartis’ Capstar flea adulticide, the arrival of generic ivermectin heartworm preventatives, and a review of products in development.  Orders placed before December 15 will receive a discounted price of $3,250.  After that time, the regular price of $4,000 will be charged.  To order your copy of the report, please contact us at lfondon@brakkeconsulting.com  or call (972) 243-4033.  **************************************************************** Company News Releases >  Bayer AG’s supervisory board is expected to approve a plan transforming the group’s four divisions into separate legal entities. Bayer has been urged by investors for years to separate its traditionally higher-margin drugs unit from its chemicals business.  The company has previously announced plans to putView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/23500\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2001-12-07T18:51:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-04-14T07:01:03+00:00\" \/>\n<meta name=\"author\" content=\"Brakke Consulting\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brakke Consulting\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/#article\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/\"},\"author\":{\"name\":\"Brakke Consulting\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/#\\\/schema\\\/person\\\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"headline\":\"Animal Health News & Notes for December 7, 2001\",\"datePublished\":\"2001-12-07T18:51:17+00:00\",\"dateModified\":\"2018-04-14T07:01:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/\"},\"wordCount\":1517,\"articleSection\":[\"Newsletter\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/\",\"url\":\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/#website\"},\"datePublished\":\"2001-12-07T18:51:17+00:00\",\"dateModified\":\"2018-04-14T07:01:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/#\\\/schema\\\/person\\\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"breadcrumb\":{\"@id\":\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/brakkeconsulting.com\\\/23500\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/brakkeconsulting.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Animal Health News & Notes for December 7, 2001\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/#website\",\"url\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/#\\\/schema\\\/person\\\/a5d2c4b59040e54bfe8f4f41f77e04d6\",\"name\":\"Brakke Consulting\",\"url\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/author\\\/i5ww2018\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/23500\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"**************************************************************** Brakke Consulting’s Animal Health News & Notes for December 7, 2001 Copyright © Brakke Consulting, Inc. **************************************************************** The 2001 Brakke Flea & Heartworm Study is now available. One more week to receive the discounted price – ORDER YOUR COPY NOW! Each fall, Brakke Consulting updates its annual report on the US Flea Control and Heartworm Markets.  In addition to updated sales figures for the major products, the study includes two new surveys of small animal veterinarians and retail pet stores, as well as a special section covering the effect of the September 11 terrorist attacks on veterinary income.  The study also includes information on Fort Dodge’s new ProHeart 6 heartworm preventative, Novartis’ Capstar flea adulticide, the arrival of generic ivermectin heartworm preventatives, and a review of products in development.  Orders placed before December 15 will receive a discounted price of $3,250.  After that time, the regular price of $4,000 will be charged.  To order your copy of the report, please contact us at lfondon@brakkeconsulting.com  or call (972) 243-4033.  **************************************************************** Company News Releases >  Bayer AG’s supervisory board is expected to approve a plan transforming the group’s four divisions into separate legal entities. Bayer has been urged by investors for years to separate its traditionally higher-margin drugs unit from its chemicals business.  The company has previously announced plans to putView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/23500\/","og_site_name":"Brakke Consulting Website","article_published_time":"2001-12-07T18:51:17+00:00","article_modified_time":"2018-04-14T07:01:03+00:00","author":"Brakke Consulting","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Brakke Consulting","Tempo estimado de leitura":"8 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/23500\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/23500\/"},"author":{"name":"Brakke Consulting","@id":"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"headline":"Animal Health News & Notes for December 7, 2001","datePublished":"2001-12-07T18:51:17+00:00","dateModified":"2018-04-14T07:01:03+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/23500\/"},"wordCount":1517,"articleSection":["Newsletter"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/23500\/","url":"https:\/\/brakkeconsulting.com\/23500\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/pt\/#website"},"datePublished":"2001-12-07T18:51:17+00:00","dateModified":"2018-04-14T07:01:03+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/23500\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/23500\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/23500\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Animal Health News & Notes for December 7, 2001"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/pt\/#website","url":"https:\/\/brakkeconsulting.com\/pt\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/pt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6","name":"Brakke Consultoria","url":"https:\/\/brakkeconsulting.com\/pt\/author\/i5ww2018\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=23500"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23500\/revisions"}],"predecessor-version":[{"id":25109,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23500\/revisions\/25109"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=23500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=23500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=23500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}